The annual J.P. Morgan Healthcare Conference, often called the Superbowl of biotech, kicked off on Jan. 8, 2018.
Over 450 companies will be presenting, including Celgene (NASDAQ: CELG), Pfizer (NYSE: PFE), and Johnson & Johnson (NYSE: JNJ), and over 9,000 people (including The Motley Fool's Kristine Harjes) will be attending. But don't worry -- The Motley Fool's healthcare team will keep you informed about the most important announcements and analysis. Check back daily for updates!
Continue Reading Below
- Why Exact Sciences Is Tumbling Today
- 5 Things You Need to Know From Celgene's J.P. Morgan Presentation
- The 1 Word That Explains Why Pfizer's Future Looks Brighter Than Its Past
- 10 Things to Expect From Vertex Pharmaceuticals in 2018
- Johnson & Johnson Wants to Create a Crisis -- and That's Great for Investors
PS -- if you're interested in checking out how much things have changed since this time in 2017, here's last year's landing page.
10 stocks we like better than Johnson & JohnsonWhen investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has tripled the market.*
David and Tom just revealed what they believe are the 10 best stocks for investors to buy right now… and Johnson & Johnson wasn't one of them! That's right -- they think these 10 stocks are even better buys.
Click here to learn about these picks!
*Stock Advisor returns as of January 2, 2018
Kristine Harjes owns shares of Johnson & Johnson. The Motley Fool owns shares of and recommends Celgene and Johnson & Johnson. The Motley Fool recommends Vertex Pharmaceuticals. The Motley Fool has a disclosure policy.